Member Info for Vander

Some links to support this - please indulge me

1) The MOU with NAMPOL is simply a continuation of the previous longstanding arrangement and the signing ceremony was a necessary preparation for the ICAO audit
https://www.namibiansun.com/news/airports-security-shocker2018-09-10

2) WASS have an MOU covering 3 airports signed 2015
There are still supporters for WASS in NCAA and the works ministry and it seems NAC and the police are still in negotiation- there is no contract yet

https://www.namibian.com.na/181133/archive-read/Nam-security-chiefs-reject-British-firm

'His comments come at a time when there is speculation that some officials are dragging their feet on signing the agreement between the police and the NAC because they still want the British company to take charge.

A draft document seen by The Namibian shows that the NAC and the police were supposed to sign the agreement this year'

3) NAC poor management/frequent change of CEO with legal disputes with contractors from previous regimes

https://allafrica.com/stories/201804260523.html
Kauta told Mutorwa that NAC is currently fighting legal battles with seven contracting companies, many of which are Chinese construction companies, an Egyptian middleman who supplies security equipment and a local engineering consulting firm.

4) Safety is till poor- runaway baggage trolleys
https://www.express.co.uk/travel/articles/1033290/luggage-namibia-airport-viral-video-flights-baggage
5) The corrective plan required in 60 days
, but unlikely to be sustainable
https://www.namibian.com.na/183854/archive-read/Govt-told-to-start-airport-security-corrective-plan

'The country was also told to develop a strategic plan to continuously improve performance on a sustainable basis'.

I had not realised before but the recently signed MOU with Nampol was almost certainly an exercise in purely providing an audit able document to icao

Sorry to be a pain- any evidence to support your views?

Can I check: NAC have had a long-standing Verbal agreement with Nampol to provide Namibian airport security for the 8 airports. For the purposes of the icao audit focusing on security they had to formalise the agreement into a written MOU to last 5 years Does this have the same status as a contract? Wass has a mou for 3 of the airports after all They scored 75 percent compliance on the audit with areas to be addressed over the subsequent 60 days. In particular they need to show that improvements can be applied on a sustainable basis. Are Nampol likely to be a long term solution? The same people who have underperformed to date It’s a shame that NAC have not had a ceo who has remained in place long enough for PF to secure the contract. The company still have ministry support- aren’t they NACs superiors?

Thanks gibbo Your 2nd point worries me much more than the 1st given the hotspots wsg inhabits Do we have any historical guide from the SL negotiations re timescale between contract drafting and execution? Will they have been liaising with HMG as per Iran?

Can I check what the process of drafting a contract entailed? Presumably it was not a solitary process conducted by PF in his hotel room. Presumably a back and forth detailed agreement with the client over a number of years? What are the blocks/ risks to the contract being executed? What stops it being signed and progressed in a short timeframe. The SP did not increase with the rns- surely the likelihood of success once you get to drafted contracts is higher than zero???

Its a good point considering how this impacts on a potential AZ deal.
They may focus on one vaccine and have enough info to proceed with upfront payment etc.
Alternatively they may wish to deepen the relationship, integrate nuvec more fully into their oncology/vaccine programme, and test multiple drug candidates, with remuneration initially in devmt costs etc. This could be better in the long run

FWIW consider starpharma dendrimer platform which may or may not act as a guide. They are not much more advanced than nuvec-still preclinical- we are at least where they were in 2015. Will the payments will be similar?
1) 1st deal Sept 2012: initial evaluation
https://www.starpharma.com/news/130
2)2nd deal in april 2014: expands the collaboration, funds preclinical programme,test multiple drugs
https://starpharma.com/news/194
https://www.sbs.com.au/news/starpharma-extends-astrazeneca-deal
3) Sept 2015 Multi product licence agreement
https://www.starpharma.com/news/247
4) Dec 2015: 2nd drug chosen
https://starpharma.com/news/265

5) April 2017 Milestone payment
https://starpharma.com/news/310
https://starpharma.com/news/316

6)Aug 2018 positive preclinical results and 1st patent published

https://starpharma.com/news/story/astrazenecaas-dep-bcl2xl-inhibitors-show-compelling-efficacy-and-synergy-in-combination

Welcome to. The board trustatrade! Please feel free to post your research and add to informed discussion AnthonyJames- yes agree with your sentiments- but who knows- either way the next medimmune rns is likely to be positive with evidence of progress. I think their aim is to fully develop MSN’s as a carrier and we are lucky they have chosen us and Cornell to do so

Combinations of treatments in oncology/ cancer Hmmm....nuvec could be good for this- see last rns

‘Big pharma raises bet on biotech as frontier for growth’ See today’s FT- interesting article Underpinning these acquisitions is a mutually beneficial exchange: biotech’s intellectual property in return for big pharma’s scale and reach, and for investors a potentially large payday Particularly relevant for combination treatments on oncology using genomic/genetic information. Also drug discovery platforms whereby Pharma acquire a key technology to repleshnish their pipelines. Prior collaborations important to subsequent acquisitions The majority of Pharma pipeline now come from external acquisitions Sorry unable to post link from mobile

My issue with a feb deadline is how can medimmune commit millions if there is still no guarantee that nuvec can be manufactured reliably at scale ie with consistency intra and inter batch ie monodisperse, spikes included Maybe Hugh or Nigel or another nuvec aficionado can clarify

Thanks woolol. I was not talking to myself earlier. Bidnolid post was deleted Btw re synergies with Cornell- they could combine the spikes with the dots. The common denominator is medimmune

My previous point was that medimmune may not care about exclusivity. They may care more about getting a product that works. If so it will mean a few million upfront versus a few hundred million in milestone/ royalities. I am only speculating- others may have a different view My main concern is that the medimmune deal happens

I agree that medi deal is key and expect it to happen for a number of reasons inc the length of current collaboration, the medi commitment to develop a non lipid and non viral nanoparticle, their collaboration with a similar ultra small msn which has synergies with ours and which paid for the use 15 million lab In 2015 and all subsequent development costs, the positive results of nuvec to date with superiority vs an industry standard polymer, inherent Advantages of msns versus npls, the patent for spikes etc etc The challenges are that despite positive pre clinical data MSN’s are early in clinical translation- only c dots have been trialled in humans- but there has been a big increase in research papers and reviews in the last year so that will change hopefully and silica has been given GRAS (generally regarded as safe) status by fda. The c dots were safe in 2014 trial and results are due out on humans on 2 more trials this year I think. C dots and nuvec both have unique selling points Given the above, I agree the medi deal is key and will mean a much higher share price.

N4p spoke at bionow oncology 2 days ago- on advanced delivery systems and manufacturing. Good that they seen as experts and are networking Recent rns- every 2-3 weeks. Last 20 th Dec. The SP does not necessarily improve with rns despite all recently being positive Hopefully we will get a medimmune update soon. We should get a deal but unclear when. Does the low volume SP drift suggest market does not believe medimmune will not exercise exclusivity rights by feb? Better if they work out an optimal product which will make it into clinical trials- how long will that take? We can progress collaborations with others after feb- if medi do not take up exclusivity. We can still do a deal with medi subsequent to that

Any thoughts?

Great we can go back to scouring Muscat airport videos for PF- it’s been approx 7 months so there will be hours of new footage

Sorry Balders (not ballers) - typos

My expectation is that eskers will post a YouTube clip showing PF shaking hands with local dignitaries, surrounded by armed security guards and ballers sitting on a donkey swatting flies. Maybe I am wrong and they will be sitting ina 5 star Zanzibar resort sipping pine coladas writing an rns On a crunched up piece of paper

Zanzibar does sounds too big and uncomplicated to be a prime mover for wsg rather than a large well established international competitor PF would be much more effusive in dangling such a delectable carrot Wsg came quite close in landing Namibia with a number of ministry supporters. Unfortunately links with an allegedly corrupt official, and competing interests with a nationalistic agenda did not help. Shame for wsg that the recent audit achieved a mediocre pass. A project the size of SL or Namibia would be a positive hors d’deuvre whilst we wait for the big one, and expands our African foothold. They need concrete results to build market confidence- no more grandiose speculation